Objectives: The aim of our study was to determine the cost-effectiveness of coronary artery disease (CAD) diagnostic parameters in a clinical laboratory setting. Design and methods: The effectiveness of apolipoproteins, lipoproteins and high sensitivity C-reactive protein (hs-CRP) supplementary to Framingham scoring data within a CAD risk assessment procedure was established in 221 CAD patients and 289 controls. The total costs of diagnostic procedures were calculated and incremental cost-effectiveness analysis was applied. Results: A diagnostic strategy employing Framingham calculation followed by apolipoprotein A-I (apoA-I) had the lowest cost per additional successfully diagnosed patient than the same strategy followed by hs-CRP in the low (2.63 vs. 24.47 euros) and intermediate-risk groups (2.96 vs. 122.85 euros). in the high-risk group the diagnostic strategy employing apoA-I saved 9.14 euros in comparison to the strategy employing hs-CRP. Conclusion: Cost-effectiveness analysis o...f different diagnostic markers results in improved identification of at-risk patients at a lower health cost for society.
TY - JOUR
AU - Bogavac-Stanojević, Nataša
AU - Petrova, Guenka
AU - Jelić-Ivanović, Zorana
AU - Memon, Lidija
AU - Spasić, Slavica
PY - 2007
UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/903
AB - Objectives: The aim of our study was to determine the cost-effectiveness of coronary artery disease (CAD) diagnostic parameters in a clinical laboratory setting. Design and methods: The effectiveness of apolipoproteins, lipoproteins and high sensitivity C-reactive protein (hs-CRP) supplementary to Framingham scoring data within a CAD risk assessment procedure was established in 221 CAD patients and 289 controls. The total costs of diagnostic procedures were calculated and incremental cost-effectiveness analysis was applied. Results: A diagnostic strategy employing Framingham calculation followed by apolipoprotein A-I (apoA-I) had the lowest cost per additional successfully diagnosed patient than the same strategy followed by hs-CRP in the low (2.63 vs. 24.47 euros) and intermediate-risk groups (2.96 vs. 122.85 euros). in the high-risk group the diagnostic strategy employing apoA-I saved 9.14 euros in comparison to the strategy employing hs-CRP. Conclusion: Cost-effectiveness analysis of different diagnostic markers results in improved identification of at-risk patients at a lower health cost for society.
PB - Pergamon-Elsevier Science Ltd, Oxford
T2 - Clinical Biochemistry
T1 - Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers
VL - 40
IS - 16-17
SP - 1180
EP - 1187
DO - 10.1016/j.clinbiochem.2007.07.004
ER -
@article{
author = "Bogavac-Stanojević, Nataša and Petrova, Guenka and Jelić-Ivanović, Zorana and Memon, Lidija and Spasić, Slavica",
year = "2007",
abstract = "Objectives: The aim of our study was to determine the cost-effectiveness of coronary artery disease (CAD) diagnostic parameters in a clinical laboratory setting. Design and methods: The effectiveness of apolipoproteins, lipoproteins and high sensitivity C-reactive protein (hs-CRP) supplementary to Framingham scoring data within a CAD risk assessment procedure was established in 221 CAD patients and 289 controls. The total costs of diagnostic procedures were calculated and incremental cost-effectiveness analysis was applied. Results: A diagnostic strategy employing Framingham calculation followed by apolipoprotein A-I (apoA-I) had the lowest cost per additional successfully diagnosed patient than the same strategy followed by hs-CRP in the low (2.63 vs. 24.47 euros) and intermediate-risk groups (2.96 vs. 122.85 euros). in the high-risk group the diagnostic strategy employing apoA-I saved 9.14 euros in comparison to the strategy employing hs-CRP. Conclusion: Cost-effectiveness analysis of different diagnostic markers results in improved identification of at-risk patients at a lower health cost for society.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers",
volume = "40",
number = "16-17",
pages = "1180-1187",
doi = "10.1016/j.clinbiochem.2007.07.004"
}
Bogavac-Stanojević, N., Petrova, G., Jelić-Ivanović, Z., Memon, L.,& Spasić, S.. (2007). Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 40(16-17), 1180-1187.
https://doi.org/10.1016/j.clinbiochem.2007.07.004
Bogavac-Stanojević N, Petrova G, Jelić-Ivanović Z, Memon L, Spasić S. Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers. in Clinical Biochemistry. 2007;40(16-17):1180-1187.
doi:10.1016/j.clinbiochem.2007.07.004 .
Bogavac-Stanojević, Nataša, Petrova, Guenka, Jelić-Ivanović, Zorana, Memon, Lidija, Spasić, Slavica, "Cost-effectiveness analysis in diagnosis of coronary artery disease: Choice of laboratory markers" in Clinical Biochemistry, 40, no. 16-17 (2007):1180-1187,
https://doi.org/10.1016/j.clinbiochem.2007.07.004 . .
